Buoyed By Big Offers And Repository of Data, Aurobindo Branches Out Into CRAMS Business With Aurosource
This article was originally published in PharmAsia News
Executive Summary
HYDERABAD, India - Athough a relatively late entrant into the contract research and manufacturing space in India, Aurobindo Pharma with its new logo "Nothing compromised" thinks there is still enough room to forge credible relationships with Western companies for newly floated CRAMS unit Aurosource
You may also be interested in...
With Oxygen Healthcare Buy, India's Piramal Healthcare Breathes More Life Into Its Chemistry Skills
MUMBAI - Flush with $3.72 billion from its much publicized deal struck last year with Abbott Laboratories for its India prescriptions business, Piramal Healthcare is eyeing strategic acquisitions to strengthen its remaining businesses spanning contract research and manufacturing services, OTC drugs and critical care medications
With Oxygen Healthcare Buy, India's Piramal Healthcare Breathes More Life Into Its Chemistry Skills
MUMBAI - Flush with $3.72 billion from its much publicized deal struck last year with Abbott Laboratories for its India prescriptions business, Piramal Healthcare is eyeing strategic acquisitions to strengthen its remaining businesses spanning contract research and manufacturing services, OTC drugs and critical care medications
Pfizer Deal To Help Propel Aurobindo's Revenues To $2 Billion In Three Years
HYDERABAD, India - With fifteen manufacturing sites under its belt and a comprehensive outsourcing deal with Pfizer, India's Aurobindo Pharma expects to see a huge bounce in its revenues from the present $800 million to over $2 billion in a span of three years